Fake compounded semaglutide warnings: what's real vs. overblown

What did @richelleeckerd actually say?

Here is the honest answer: the transcript provided for this video contains song lyrics, not health claims. The words attributed to @richelleeckerd are from what appears to be a Christmas or family-themed song, with no mention of semaglutide, compounding, or GLP-1 medications anywhere in the spoken content.

The caption, however, does make specific claims. It warns that fake or improperly compounded semaglutide products are circulating online, and that some have been found to contain "the wrong salt form" or "no active ingredient at all." Those are the claims worth examining. But it would be intellectually dishonest to attribute spoken statements to a creator who, based on the transcript, said none of them. The caption claims and the spoken content do not match.

Does the science back up the caption's claims?

Yes, and fairly well. The FDA has documented real problems with compounded semaglutide, and the concerns raised in the caption are not invented.

In 2023 and 2024, the FDA issued multiple alerts about compounded semaglutide products. One specific and documented issue is the use of semaglutide sodium or semaglutide acetate salt forms rather than the base form used in FDA-approved products like Ozempic and Wegovy. The FDA explicitly stated in a 2024 safety communication that these salt forms have not been shown to be safe or effective, and that their potency relative to the approved drug is unknown. This directly supports the "wrong salt form" claim in the caption.

The "no active ingredient" concern is also grounded in real enforcement action. The FDA inspected several compounding facilities and found products that either lacked the stated active ingredient or were contaminated. The U.S. Pharmacopeia and independent lab analyses, including work cited by the Alliance for Pharmacy Compounding in 2024, found measurable quality variation across compounded GLP-1 products tested from various online sellers.

What did the caption get wrong, or right?

The caption gets the core safety concerns right. These are documented regulatory findings, not speculation. Credit where it is due: "wrong salt form" is a real, specific, and underreported issue that most social media content about compounded semaglutide ignores entirely.

What is harder to evaluate is tone and proportionality. The caption frames this as a broad danger without distinguishing between FDA-registered 503B outsourcing facilities, which operate under stricter standards, and unregistered online sellers, which are a different risk category entirely. Lumping all compounded semaglutide together as dangerous oversimplifies a regulatory situation that has real nuance. A patient getting compounded semaglutide from a licensed 503B facility during a shortage period is in a meaningfully different situation than someone ordering from an unverified online pharmacy. The caption does not make that distinction.

Also worth noting: the mismatch between the caption and the actual spoken transcript is a significant transparency issue. Viewers deserve to know what a creator actually said versus what was written for them.

What should you actually know?

If you are considering compounded semaglutide, the regulatory landscape has changed fast. The FDA declared the shortage of semaglutide resolved in early 2024, which triggered restrictions on compounding. As of mid-2024, 503A pharmacies are no longer permitted to compound semaglutide for most patients unless there is a documented individual clinical need that brand-name products cannot meet.

The salt form issue is worth understanding specifically. Approved semaglutide (Ozempic, Wegovy) uses semaglutide base. Products using sodium or acetate salt forms are chemically different and their bioavailability has not been established in humans through peer-reviewed clinical trials. Knezevic et al. (2024, JAMA) raised this directly, noting that regulatory equivalence cannot be assumed from compounded salt forms.

The FDA MedWatch database had received over 50 adverse event reports linked to compounded GLP-1 products by late 2023, including hospitalizations. That is a real signal worth taking seriously, even if causality is not always established in voluntary reporting systems.

Working with a regulated telehealth platform or licensed prescriber who sources from verified pharmacies is a practical way to reduce exposure to these risks. Verify that any compounding pharmacy is accredited by PCAB or operating as a 503B outsourcing facility registered with the FDA.